The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaProlonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibEvaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib.Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase.Management of Bcr-Abl-positive leukemias with dasatinib.Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyLong-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.S-phase fraction as response marker in patients with chronic myeloid leukemia.Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.Imatinib mesylate induced immune thrombocytopenia.PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
P2860
Q26749324-E5D6A6F7-EFD1-45E7-BE70-C72E428A2522Q33378240-6E4C4FA5-D384-40EF-8ED6-6D7618E45EA2Q33384955-B628F2FF-9593-4953-B270-4F11ABD6FA5EQ33394812-3C8789C4-362D-4C43-96EB-740A339FD5BDQ33395597-A9EE6D45-5590-4338-B209-DFC2DC551078Q33398485-5E26513E-6A1B-4147-8F13-0FCCB5769680Q33408049-2BDC2612-8950-4416-AD73-BCFCD319548AQ33926222-5CC8A737-D480-4D14-9A21-7A38A3596073Q34832286-6AA5B732-5EB4-4205-B053-64AD6AD48A4FQ35073857-0DAEFBE0-179E-40D0-B1D0-AA9F84133753Q35816396-D0CC506D-BD7E-4AD7-BF73-98EDCD9EAAFAQ36387433-BDB4EABE-004E-440B-97FA-8A9A9A5FF482Q37004660-70DC45B8-35FB-44A0-A0B4-625A66BCAFA9Q37306890-AF380415-D99D-44C8-85CE-269B61C50282Q37461942-314F36BF-4232-4A96-B20C-68C1498E08F7Q38216677-52A49FCC-11E5-4E6E-8D52-82F018DF3839Q38392679-585930C3-A70A-4062-9455-C2313C92FBD6Q41877522-518BAEA4-F346-4005-9B08-9B9AD7692D2CQ44737485-3A2DA8AE-2559-44CB-9A80-44D8F1BF4A6BQ45301057-3F274C70-374F-4EDF-94AA-82F5579D057EQ45951572-4C429581-78BF-4672-8477-A2FBCC838A9FQ46216897-159E3D37-5BFC-4A82-82D3-6841DD3A2BFBQ46958481-4B2043E8-1E9E-46C1-871C-C2810FE22394Q47667785-60A88601-E963-4AFD-8862-73AB045D6925Q48549224-EB092DAA-672B-4235-9F89-7F152A503920Q50457803-406EA297-1180-4668-B210-1A3BFD0C7B21Q54595707-A30FE33A-ACA7-4D51-A3D7-A45D3BA2E3B4
P2860
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The significance of myelosuppr ...... ous leukemia in chronic phase.
@ast
The significance of myelosuppr ...... ous leukemia in chronic phase.
@en
type
label
The significance of myelosuppr ...... ous leukemia in chronic phase.
@ast
The significance of myelosuppr ...... ous leukemia in chronic phase.
@en
prefLabel
The significance of myelosuppr ...... ous leukemia in chronic phase.
@ast
The significance of myelosuppr ...... ous leukemia in chronic phase.
@en
P2093
P50
P356
P1433
P1476
The significance of myelosuppr ...... ous leukemia in chronic phase.
@en
P2093
B Nebiyou Bekele
Debra Resta
Moshe Talpaz
Thomas B Sneed
P304
P356
10.1002/CNCR.11863
P407
P50
P577
2004-01-01T00:00:00Z